<DOC>
	<DOC>NCT01234558</DOC>
	<brief_summary>The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.</brief_summary>
	<brief_title>Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
	<criteria>diagnosis of major depressive disorder consistent with DSMIVTR current episode greater than 8 weeks in duration Hamilton Depression score &gt;/ 21 less than 25% reduction in depression during current episode assessed by ATRQ Axis diagnosis of other psychiatric disorders Experiencing hallucinations, delusions, other psychotic symptomatology ECT during current episode</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>depression</keyword>
	<keyword>NMDA antagonist</keyword>
	<keyword>treatment resistant</keyword>
</DOC>